ALTERITY THERAPEUTICS LIMITED
Target Market Determination (TMD) for the free attaching SPP options offered under the Company's prospectus dated 29 December 2023
December 29, 2023December 29, 2023Alterity Therapeutics
Target Market Determination (TMD) for the free attaching SPP options offered under the Company's prospectus dated 29 December 2023
Post navigation
Previous Post
Presentation to Extraordinary General MeetingNext Post
Target Market Determination (TMD) for the placement options offered under the Company's prospectus dated 29 December 2023
Related Posts
XBRL 30 June 2021 filed with the SEC
September 3, 2021August 16, 2022
Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases
November 4, 2021August 16, 2022
Prana Provides Clinical Trials Update
July 17, 2013August 16, 2022
Leave a Reply Cancel reply
Your email address will not be published.Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
Type in the text displayed above
Δ
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Alterity Therapeutics Ltd. published this content on 29 December 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 December 2023 03:41:42 UTC.
